Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro

Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro

Chronic treatment of renal cell carcinoma (RCC) with the tyrosine kinase inhibitor sunitinib (ST) inevitably induces resistance and tumor re-activation. This study investigated whether adding the natural compound sulforaphane (SFN) with its anti-cancer properties could improve ST efficacy in vitro....

Full description

Bibliographic Details
Main Authors: Igor Tsaur, Anita Thomas, Emine Taskiran, Jochen Rutz, Felix K.-H. Chun, Axel Haferkamp, Eva Juengel, Roman A. Blaheta
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
renal cell carcinoma
sulforaphane
sunitinib
growth
proliferation
complementary alternative medicine (CAM)
Online Access:https://www.mdpi.com/2072-6694/14/19/4643

Internet

https://www.mdpi.com/2072-6694/14/19/4643

Similar Items